These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

578 related articles for article (PubMed ID: 37969727)

  • 1. Current research trends of nanomedicines.
    Liu Q; Zou J; Chen Z; He W; Wu W
    Acta Pharm Sin B; 2023 Nov; 13(11):4391-4416. PubMed ID: 37969727
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A review of the current scientific and regulatory status of nanomedicines and the challenges ahead.
    Hock SC; Ying YM; Wah CL
    PDA J Pharm Sci Technol; 2011; 65(2):177-95. PubMed ID: 21502077
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety and Toxicological Considerations of Nanomedicines: The Future Directions.
    Patel P; Shah J
    Curr Clin Pharmacol; 2017; 12(2):73-82. PubMed ID: 28486906
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Manipulation of protein corona for nanomedicines.
    Li T; Wang Y; Zhou D
    Wiley Interdiscip Rev Nanomed Nanobiotechnol; 2024; 16(4):e1982. PubMed ID: 39004508
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Recent advances in dual- and multi-responsive nanomedicines for precision cancer therapy.
    Zhang Y; Li J; Pu K
    Biomaterials; 2022 Dec; 291():121906. PubMed ID: 36395660
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Current understandings and clinical translation of nanomedicines for breast cancer therapy.
    Jiang Y; Jiang Z; Wang M; Ma L
    Adv Drug Deliv Rev; 2022 Jan; 180():114034. PubMed ID: 34736986
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cell membrane cloaked nanomedicines for bio-imaging and immunotherapy of cancer: Improved pharmacokinetics, cell internalization and anticancer efficacy.
    Hussain Z; Rahim MA; Jan N; Shah H; Rawas-Qalaji M; Khan S; Sohail M; Thu HE; Ramli NA; Sarfraz RM; Abourehab MAS
    J Control Release; 2021 Jul; 335():130-157. PubMed ID: 34015400
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Emerging Anesthetic Nanomedicines: Current State and Challenges.
    Zhang S; Wang Y; Zhang S; Huang C; Ding Q; Xia J; Wu D; Gao W
    Int J Nanomedicine; 2023; 18():3913-3935. PubMed ID: 37489141
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Physiological determinants and plausible '6R' roadmap for clinical success of nanomedicines.
    Shahiwala A
    Nanomedicine (Lond); 2023 Aug; 18(18):1207-1222. PubMed ID: 37650539
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Emerging nanomedicines of paclitaxel for cancer treatment.
    Chen Q; Xu S; Liu S; Wang Y; Liu G
    J Control Release; 2022 Feb; 342():280-294. PubMed ID: 35016919
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nanomedicines: An approach to treat placental insufficiency and the current challenges.
    van Kammen CM; van Woudenberg SJ; Schiffelers R; Terstappen F; Lely AT
    J Control Release; 2023 Aug; 360():57-68. PubMed ID: 37330012
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Trends in Nanomedicines for Cancer Treatment.
    do Nascimento T; Todeschini AR; Santos-Oliveira R; de Souza de Bustamante Monteiro MS; de Souza VT; Ricci-Júnior E
    Curr Pharm Des; 2020; 26(29):3579-3600. PubMed ID: 32186271
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Protein corona: challenges and opportunities for targeted delivery of nanomedicines.
    Jiang Z; Chu Y; Zhan C
    Expert Opin Drug Deliv; 2022 Jul; 19(7):833-846. PubMed ID: 35738018
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Nanomedicine-based drug targeting for psoriasis: potentials and emerging trends in nanoscale pharmacotherapy.
    Rahman M; Akhter S; Ahmad J; Ahmad MZ; Beg S; Ahmad FJ
    Expert Opin Drug Deliv; 2015 Apr; 12(4):635-52. PubMed ID: 25439967
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cancer nanomedicine toward clinical translation: Obstacles, opportunities, and future prospects.
    Zhang P; Xiao Y; Sun X; Lin X; Koo S; Yaremenko AV; Qin D; Kong N; Farokhzad OC; Tao W
    Med; 2023 Mar; 4(3):147-167. PubMed ID: 36549297
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Challenging the fundamental conjectures in nanoparticle drug delivery for chemotherapy treatment of solid cancers.
    Yang J; Wang X; Wang B; Park K; Wooley K; Zhang S
    Adv Drug Deliv Rev; 2022 Nov; 190():114525. PubMed ID: 36100142
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Polyprodrug Nanomedicines: An Emerging Paradigm for Cancer Therapy.
    Yang K; Yang Z; Yu G; Nie Z; Wang R; Chen X
    Adv Mater; 2022 Feb; 34(6):e2107434. PubMed ID: 34693571
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Stimuli-responsive prodrug-based cancer nanomedicine.
    Xie A; Hanif S; Ouyang J; Tang Z; Kong N; Kim NY; Qi B; Patel D; Shi B; Tao W
    EBioMedicine; 2020 Jun; 56():102821. PubMed ID: 32505922
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Disentangling Biomolecular Corona Interactions With Cell Receptors and Implications for Targeting of Nanomedicines.
    Aliyandi A; Zuhorn IS; Salvati A
    Front Bioeng Biotechnol; 2020; 8():599454. PubMed ID: 33363128
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Covalent organic framework nanomedicines: Biocompatibility for advanced nanocarriers and cancer theranostics applications.
    Singh N; Kim J; Kim J; Lee K; Zunbul Z; Lee I; Kim E; Chi SG; Kim JS
    Bioact Mater; 2023 Mar; 21():358-380. PubMed ID: 36185736
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 29.